For AstraZeneca

Country President of Czech Republic Slovakia)

Robert Weigl (Market Access Director Europe)

Vladimír Hraško (Medical Director Slovakia)

For MZ SR:

Director of the Department of Classification and Pricing: PharmDr. Miriam Vuleva, MBA

Medical Technology Officer PharmDr. Ing. Ivona Malovecky, PhD.

Categorisation and pricing officers: PharmDr. Barbora Murányi

At the Ministry's suggestion a meeting with Astra Zeneca was organised. Theme the meeting was the availability of Lynparza for Slovak patients. Lynparza is a registered medicinal product not included in the list of categorised medicinal products, therefore in the Slovak Republic can be reimbursed on the basis of public health insurance by insurance companies in accordance with § 88 of Law 363/2011 Z. z. z. Amendment of legislation Lynparza was given an intolerable supplement as of January 2018. Representatives Companies welcomed the Ministry's interest in solving the problem and assured we, that they care about the health of patients and stressed that they approach Slovak patients as well as patients of all EU Member States.

The holder of the registration informed us, that he fully understands the new conditions for reimbursement of medicines pursuant to § 88 of Law 363/2011 Z. z also the need to agree on the conditions for reimbursement under the transitional period until the end of 2018. The registration holder shall conduct negotiations with the insurance undertaking, aimed at ensuring that patients are not exposed to surcharges due to changes to the law for medicines reimbursed pursuant to § 88 of Act 363/2011 Coll., . Possible agreement must be approved by the highest management of the company, not local by representation. Director Vuleva informed them in detail about all of them. the particulars resulting from the amendment to Law No 363/2011 Z. z. which is in Article 2 Stability is important for the holder of the registration system and a level playing field. The company confirmed that in currently in transition, representation of the company in Slovakia however, it remains and all medicines remain available as before. Mrs. The Director stated in the discussion that, in accordance with current legislation the holder may submit an application for inclusion in the list of categorised medicinal products. The Ministry, as the legislative body, shall act in a transparent manner, and by law.